AMNEAL PHARMACEUTICALS, INC. Financing Cash Flow
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Financing Cash Flow of $20.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $79.36M.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$59.05M.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$10.12M.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $59.44M.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was -$31.53M.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was -$211.79M.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was -$212.57M.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$106.62M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $79.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $20.31M 10-Q · filed 2026-08-06 | $10.19M derived: sum of 3 quarters · filed 2026-08-06 | $69.63M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$59.05M 10-Q · filed 2026-05-07 | -$69.17M derived: sum of 2 quarters · filed 2026-05-07 | -$9.73M derived: sum of 3 quarters · filed 2026-05-07 | -$51.42M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$10.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $49.32M derived: sum of 2 quarters · filed 2026-02-27 | $7.64M derived: sum of 3 quarters · filed 2026-08-06 | -$31.53M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $59.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $17.76M derived: sum of 2 quarters · filed 2026-08-06 | -$21.41M 10-Q · filed 2025-11-06 | -$82.61M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$41.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$80.85M 10-Q · filed 2026-08-06 | -$142.06M derived: sum of 3 quarters · filed 2026-08-06 | -$234.40M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$39.17M 10-Q · filed 2026-05-07 | -$100.37M derived: sum of 2 quarters · filed 2026-05-07 | -$192.72M derived: sum of 3 quarters · filed 2026-05-07 | -$227.80M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$61.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$153.55M derived: sum of 2 quarters · filed 2026-02-27 | -$188.64M derived: sum of 3 quarters · filed 2026-02-27 | -$211.79M 10-K · filed 2026-02-27 | |
| 2024-09-30 | -$92.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$127.43M derived: sum of 2 quarters · filed 2025-11-06 | -$150.59M 10-Q · filed 2025-11-06 | -$251.42M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | -$35.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$58.24M 10-Q · filed 2025-08-07 | -$159.07M derived: sum of 3 quarters · filed 2026-02-27 | -$245.66M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | -$23.16M 10-Q · filed 2025-05-07 | -$123.99M derived: sum of 2 quarters · filed 2026-02-27 | -$210.57M derived: sum of 3 quarters · filed 2026-02-27 | -$222.83M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | -$100.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$187.42M derived: sum of 2 quarters · filed 2026-02-27 | -$199.67M derived: sum of 3 quarters · filed 2026-02-27 | -$212.57M 10-K · filed 2026-02-27 | |
| 2023-09-30 | -$86.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$98.84M derived: sum of 2 quarters · filed 2024-11-12 | -$111.74M 10-Q · filed 2024-11-12 | -$133.91M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | -$12.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$25.16M 10-Q · filed 2024-08-09 | -$47.32M derived: sum of 3 quarters · filed 2025-02-28 | -$93.45M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | -$12.90M 10-Q · filed 2024-05-08 | -$35.07M derived: sum of 2 quarters · filed 2025-02-28 | -$81.20M derived: sum of 3 quarters · filed 2025-02-28 | -$57.95M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | -$22.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$68.30M derived: sum of 2 quarters · filed 2025-02-28 | -$45.05M derived: sum of 3 quarters · filed 2025-02-28 | -$106.62M 10-K · filed 2025-02-28 | |
| 2022-09-30 | -$46.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$22.88M derived: sum of 2 quarters · filed 2023-11-09 | -$84.45M 10-Q · filed 2023-11-09 | -$114.80M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $23.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$38.32M 10-Q · filed 2023-08-08 | -$68.67M derived: sum of 3 quarters · filed 2024-03-14 | -$112.23M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | -$61.57M 10-Q · filed 2023-05-09 | -$91.92M derived: sum of 2 quarters · filed 2024-03-14 | -$135.47M derived: sum of 3 quarters · filed 2024-03-14 | -$173.54M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$30.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$73.91M derived: sum of 2 quarters · filed 2024-03-14 | -$111.97M derived: sum of 3 quarters · filed 2024-03-14 | -$138.12M 10-K · filed 2024-03-14 | |
| 2021-09-30 | -$43.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$81.62M derived: sum of 2 quarters · filed 2022-11-07 | -$107.77M 10-Q · filed 2022-11-07 | -$119.05M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-06-30 | -$38.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$64.22M 10-Q · filed 2022-08-08 | -$75.50M derived: sum of 3 quarters · filed 2023-03-03 | -$90.31M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-03-31 | -$26.15M 10-Q · filed 2022-05-06 | -$37.43M derived: sum of 2 quarters · filed 2023-03-03 | -$52.24M derived: sum of 3 quarters · filed 2023-03-03 | -$362.32M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2020-12-31 | -$11.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$26.09M derived: sum of 2 quarters · filed 2023-03-03 | -$336.17M derived: sum of 3 quarters · filed 2023-03-03 | $131.81M 10-K · filed 2023-03-03 | |
| 2020-09-30 | -$14.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$324.89M derived: sum of 2 quarters · filed 2021-11-08 | $143.09M 10-Q · filed 2021-11-08 | $135.79M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | -$310.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $157.90M 10-Q · filed 2021-08-09 | $150.60M derived: sum of 3 quarters · filed 2022-03-01 | $143.00M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $467.98M 10-Q · filed 2021-05-07 | $460.68M derived: sum of 2 quarters · filed 2022-03-01 | $453.08M derived: sum of 3 quarters · filed 2022-03-01 | $444.01M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$14.89M derived: sum of 2 quarters · filed 2022-03-01 | -$23.97M derived: sum of 3 quarters · filed 2022-03-01 | -$45.83M 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$7.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$16.67M derived: sum of 2 quarters · filed 2020-11-06 | -$38.53M 10-Q · filed 2020-11-06 | -$257.45M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | -$9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$30.94M 10-Q · filed 2020-08-06 | -$249.86M derived: sum of 3 quarters · filed 2021-03-01 | -$167.26M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | -$21.86M 10-Q · filed 2020-05-11 | -$240.78M derived: sum of 2 quarters · filed 2021-03-01 | -$158.18M derived: sum of 3 quarters · filed 2021-03-01 | $299.06M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | -$218.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$136.32M derived: sum of 2 quarters · filed 2021-03-01 | $320.92M derived: sum of 3 quarters · filed 2021-03-01 | $287.68M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $82.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $539.84M derived: sum of 2 quarters · filed 2019-11-07 | $506.60M 10-Q · filed 2019-11-07 | $506.60M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $457.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $424.00M 10-Q · filed 2019-08-05 | $424.00M derived: sum of 3 quarters · filed 2019-08-05 | $360.22M derived: sum of 4 quarters · filed 2019-08-05 | |
| 2018-03-31 | -$33.25M 10-Q · filed 2019-05-09 | $0.00 10-Q · filed 2018-05-15 | -$33.25M derived: sum of 2 quarters · filed 2019-05-09 | -$97.02M derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | $0.00 10-K · filed 2018-03-09 | -$63.77M derived: sum of 2 quarters · filed 2018-11-07 | -$95.02M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | -$63.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$95.51M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | -$31.74M 10-Q · filed 2018-08-09 | ||||
| 2016-12-31 | -$19.50M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |